Mahoko Ikeda

Mahoko Ikeda

Auto-generated profile, based on publicly available information

Mahoko Ikeda

Department of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2015 in Annals of Clinical Microbiology and Antimicrobials
Verified
Journal Article
Open access
PDF file
MIMahoko Ikeda
Mahoko Ikeda
YYYuka Yagihara
Yuka Yagihara
KTKeita Tatsuno
Keita Tatsuno
MOMitsuhiro Okazaki
Mitsuhiro Okazaki
SOShu Okugawa
Shu Okugawa
KMKyoji Moriya
Kyoji Moriya
Bacillus cereus is one of the pathogens causing nosocomial bloodstream infections (BSIs). However, few reports have documented the antimicrobial susceptibility and clinical characteristics of Bacillus cereus BSI and the importance of empirical therapy. The aim of this study was to investigate the clinical characteristics and antimicrobial susceptibility of B. cereus isolates from patients with BSI and to analyze the impact of appropriate empirical therapy on the outcome of patients with B. cereus BSI. All adult cases of bacteremia between April 2003 and March 2012 in a teaching hospital in Tokyo, Japan were reviewed retrospectively. Clinical data were collected from the patients’ medical records and charts. Antimicrobial susceptibility testing was performed by broth microdilution method. The patients with B. cereus BSI were divided into an appropriate empirical therapy group and an inappropriate empirical therapy group. The primary outcome was all-cause mortality at 4 weeks after the start of BSI. The secondary outcome was early defervescence within 2 days after starting empirical therapy. There were 29 B. cereus bloodstream infection cases. No vancomycin, gentamicin, and imipenem-resistant isolates were found. However, 65.5 % were resistant to clindamycin and 10.3 % were resistant to levofloxacin. The main etiology was venous catheter-related (69 %). All-cause mortality at 4 weeks was not significantly different between the appropriate empirical therapy group (9 cases) and the inappropriate group (20 cases) in this study. However, early defervescence within 2 days after starting empirical therapy was significantly different (p = 0.032). The BSI of B. cereus is mostly caused by venous catheter-related infections. Appropriate empirical therapy is important to achieve early clinical resolution in B. cereus BSI. Vancomycin is one of the appropriate selections of empirical therapy for B. cereus BSI.

18 May 2021 in Gut Pathogens
Verified
Journal Article
Open access
PDF file
MIMahoko Ikeda
Mahoko Ikeda
TKTatsuya Kobayashi
Tatsuya Kobayashi
FFFumie Fujimoto
Fumie Fujimoto
YOYuta Okada
Yuta Okada
YHYoshimi Higurashi
Yoshimi Higurashi
KMKyoji Moriya
Kyoji Moriya
Background: Although Escherichia coli is the most frequently isolated microorganism in acute biliary tract infections with bacteremia, data regarding its virulence are limited. Results: Information on cases of bacteremia in acute biliary tract infection in a retrospective study was collected from 2013 to 2015 at a tertiary care hospital in Japan. Factors related to the severity of infection were investigated, including patient background, phylogenetic typing, and virulence factors of E. coli, such as adhesion, invasion, toxins, and iron acquisition. In total, 72 E. coli strains were identified in 71 cases, most of which primarily belonged to the B2 phylogroup (68.1%). The presence of the iutA gene (77.3% in the non-severe group, 46.4% in the severe group, P = 0.011) and the ibeA gene (9.1% in the non-severe group, and 35.7% in the severe group, P = 0.012) was significantly associated with the severity of infection. Among the patient characteristics, diabetes mellitus with organ involvement and alkaline phosphatase were different in the severe and non-severe groups. Conclusions: We showed that bacteremic E. coli strains from acute biliary tract infections belonged to the virulent (B2) phylogroup. The prevalence of the iutA and ibeA genes between the two groups of bacteremia severity was significantly different.

25 September 2021 in Annals of Clinical Microbiology and Antimicrobials
Verified
Journal Article
Open access
PDF file
TKTatsuya Kobayashi
Tatsuya Kobayashi
MIMahoko Ikeda
Mahoko Ikeda
YOYuki Ohama
Yuki Ohama
KMKoji Murono
Koji Murono
KIKazuhiko Ikeuchi
Kazuhiko Ikeuchi
KMKyoji Moriya
Kyoji Moriya
Background: Staphylococcus schleiferi is a gram-positive pathogenic coccus which causes canine skin and ear infections. Only four cases of human infection caused by Staphylococcus schleiferi subspecies coagulans have been reported. Herein, we present the first case of catheter-related bloodstream infection caused by S. schleiferi subspecies coagulans. Case presentation: A 62-year-old Japanese man was admitted to our hospital for examination of sigmoid colon tumor. During hospitalization, he had fever, shaking chills, and swelling at the peripheral venous catheter insertion site. Two sets of blood cultures were positive for S. schleiferi subspecies coagulans which was confirmed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), 16S ribosomal RNA sequencing and the coagulase test. The patient was successfully treated without relapse. Conclusion: To our knowledge, this is the first report of catheter-related bloodstream infection caused by S. schleiferi subspecies coagulans. S. schleiferi subsp. coagulans can be pathogenic in humans, and MALDI-TOF MS can contribute to accurate identification of S. schleiferi subspecies coagulans.

8 July 2023 in International Journal of Antimicrobial Agents
Verified
Journal Article
Open access
SOShu Okugawa
Shu Okugawa
MIMahoko Ikeda
Mahoko Ikeda
KKKosuke Kashiwabara
Kosuke Kashiwabara
TMTakashi Moritoyo
Takashi Moritoyo
TKTakao Kohsaka
Takao Kohsaka
KMKyoji Moriya
Kyoji Moriya
This study aimed to evaluate the antiviral effects and safety of nafamostat in early-onset patients with coronavirus disease 2019 (COVID-19). In this exploratory multicentre randomized controlled trial, patients were assigned to three groups within 5 days of symptom onset, with 10 participants in each group: nafamostat at either 0.2 mg/kg/h or 0.1 mg/kg/h or a standard-of-care group. The primary endpoint was area under the curve for decrease in SARS-CoV-2 viral load in nasopharyngeal samples from baseline to day 6. Of the 30 randomized patients, 19 received nafamostat. Overall, 10 patients received low-dose nafamostat, 9 patients received high-dose nafamostat, and 10 received standard-of-care. The detected viruses were Omicron strains. The regression coefficient for area under the curve for decrease in viral load as the response variable and nafamostat dose per body weight as the explanatory variable showed a significant relationship of -40.1 (95% confidence interval, -74.1 to -6.2; P = 0.022). Serious adverse events were not observed in either group. Phlebitis occurred in ca. 50% of patients treated with nafamostat. Nafamostat exerts virus load-reducing effects in patients with early-onset COVID-19.

1 November 2020 in Pancreas
Verified
Journal Article
Closed access
TSTakayuki Shinohara
Takayuki Shinohara
AOAmato Otani
Amato Otani
MYMarie Yamashita
Marie Yamashita
YWYuji Wakimoto
Yuji Wakimoto
DJDaisuke Jubishi
Daisuke Jubishi
KMKyoji Moriya
Kyoji Moriya

29 October 2023 in Heliyon
Verified
Journal Article
Open access
MIMahoko Ikeda
Mahoko Ikeda
TKTatsuya Kobayashi
Tatsuya Kobayashi
SOShu Okugawa
Shu Okugawa
FFFumie Fujimoto
Fumie Fujimoto
YOYuta Okada
Yuta Okada
KMKyoji Moriya
Kyoji Moriya
Escherichia coli is a gram-negative intestinal commensal that can also cause various infections, including urinary tract infections, biliary tract infections, neonatal meningitis, and septicemia. Although the characteristics of uropathogenic E. coli and the mechanisms of urinary tract infection have been well studied, the genetic distinctions among E. coli isolates from different types of infections have not yet been determined. This study compared the phylogenetic and virulence factors of E. coli isolates from bacteremic biliary tract infections with those from bacteremic urinary tract infections. The phylogenetic B2 group was the most prevalent in both pathogenic groups (68 % in biliary pathogenic isolates and 85 % in uropathogenic isolates), but the frequency pattern of the phylogenetic group was different. Half of the uropathogenic isolates belonged to ST95 and ST131 (51 %). Among the biliary pathogenic isolates, ST131 was the most prevalent, while the remaining half belonged to other STs outside the four major STs. The frequency of some virulence factors, such as papC, papG2, hlyA, tcpC, fyuA, kpsMT2, sat, and traT, was lower in the biliary pathogenic isolates than in the uropathogenic isolates. The frequency of phylogenetic groups and STs in MLST differed between E. coli isolates from bacteremic biliary tract infections and urinary tract infections. Additionally, some virulence factors, including adhesion and toxin gene groups, showed lower frequencies in the biliary pathogenic group than in the uropathogenic group. Studying the differences in E. coli pathovars from different infection sites is important for developing pathovar-specific targeted therapies such as vaccine therapy.